BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 17558264)

  • 1. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic management of urinary incontinence, voiding dysfunction, and overactive bladder.
    Saks EK; Arya LA
    Obstet Gynecol Clin North Am; 2009 Sep; 36(3):493-507. PubMed ID: 19932412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current management of overactive bladder.
    Cartwright R; Renganathan A; Cardozo L
    Curr Opin Obstet Gynecol; 2008 Oct; 20(5):489-95. PubMed ID: 18797274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Costantini E; Lazzeri M
    Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Soljanik I
    Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
    [No Abstract]   [Full Text] [Related]  

  • 6. Developments in the pharmacotherapy of the overactive bladder.
    Sellers DJ; McKay N
    Curr Opin Urol; 2007 Jul; 17(4):223-30. PubMed ID: 17558263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder.
    Latini JM; Giannantoni A
    Expert Opin Pharmacother; 2011 May; 12(7):1017-27. PubMed ID: 21473706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.
    Hashim H; Abrams P
    Drugs; 2004; 64(15):1643-56. PubMed ID: 15257626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacotherapy of overactive bladder.
    Athanasopoulos A
    Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies.
    Hegde SS; Mammen M; Jasper JR
    Curr Opin Investig Drugs; 2004 Jan; 5(1):40-9. PubMed ID: 14983972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overactive bladder syndrome in older people.
    Wagg AS; Cardozo L; Chapple C; De Ridder D; Kelleher C; Kirby M; Milsom I; Vierhout M
    BJU Int; 2007 Mar; 99(3):502-9. PubMed ID: 17407511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anticholinergic drugs in overactive bladder].
    Muhlstein J; Deval B
    Gynecol Obstet Fertil; 2008 Jan; 36(1):90-6. PubMed ID: 18178506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overactive bladder--a practical approach to evaluation and management.
    Madersbacher H
    J Med Liban; 2004; 52(4):220-6. PubMed ID: 16432986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the development of antimuscarinic agents for overactive bladder.
    Smith AL; Wein AJ
    Trends Pharmacol Sci; 2010 Oct; 31(10):470-5. PubMed ID: 20801529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical compounds for the treatment of overactive bladder.
    Giannitsas K; Konstantinopoulos A; Patsialas C; Athanasopoulos A; Perimenis P
    Expert Opin Ther Pat; 2009 Feb; 19(2):107-17. PubMed ID: 19441912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solifenacin in the management of the overactive bladder syndrome.
    Robinson D; Cardozo L
    Int J Clin Pract; 2005 Oct; 59(10):1229-36. PubMed ID: 16178992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of the overactive bladder with detrusitol].
    Golomb J
    Harefuah; 2000 Dec; 139(11-12):467-70. PubMed ID: 11341197
    [No Abstract]   [Full Text] [Related]  

  • 19. [Anticholinergic treatment of overactive bladder. A costly treatment with doubtful clinical effect?].
    Møller LA; Lose G
    Ugeskr Laeger; 2003 Nov; 165(47):4552-3. PubMed ID: 14677238
    [No Abstract]   [Full Text] [Related]  

  • 20. Overactive bladder in children. Part 1: Pathophysiology.
    Franco I
    J Urol; 2007 Sep; 178(3 Pt 1):761-8; discussion 768. PubMed ID: 17631323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.